Apellis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Apellis Pharmaceuticals
APLS Stock  USD 19.86  0.30  1.49%   
Apellis Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apellis Pharmaceuticals' valuation are provided below:
Gross Profit
605.7 M
Profit Margin
0.0223
Market Capitalization
2.6 B
Enterprise Value Revenue
2.6468
Revenue
1 B
There are over one hundred nineteen available fundamental signals for Apellis Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Apellis Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Apellis Pharmaceuticals Total Revenue

1.05 Billion

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 46.5 M or Selling General Administrative of 577.8 M, as well as many indicators such as Price To Sales Ratio of 3.0, Dividend Yield of 0.0 or PTB Ratio of 15.52. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Apellis Stock
Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.1 B432.7 M
Slightly volatile
Other Current Liabilities174.4 M166 M64.8 M
Slightly volatile
Total Current Liabilities339.8 M323.6 M95.5 M
Slightly volatile
Total Stockholder Equity388.7 M370.1 M128.8 M
Slightly volatile
Property Plant And Equipment Net16.8 M19.9 M10.1 M
Slightly volatile
Accounts Payable59.6 M56.8 M16.7 M
Slightly volatile
Cash319.1 M467.8 M241.4 M
Slightly volatile
Non Current Assets Total63.4 M60.4 M23.6 M
Slightly volatile
Cash And Short Term Investments351.2 M467.8 M265.6 M
Slightly volatile
Net Receivables384.5 M366.2 M80.8 M
Slightly volatile
Common Stock Total Equity9.7 K9.2 K4.9 K
Slightly volatile
Common Stock Shares Outstanding69.7 M126 M53.4 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.1 B432.7 M
Slightly volatile
Inventory149.7 M142.6 M37.2 M
Slightly volatile
Other Current Assets23.5 M38.3 M17.8 M
Slightly volatile
Other Stockholder Equity3.6 B3.4 B1.2 B
Slightly volatile
Total Liabilities374.4 M705.1 M282.4 M
Slightly volatile
Property Plant And Equipment Gross18.5 M19.9 M13.7 M
Slightly volatile
Total Current Assets1.1 B1 B409.1 M
Slightly volatile
Common Stock7.3 K13.8 K5.7 K
Slightly volatile
Other Assets19.1 M18.2 M8 M
Slightly volatile
Property Plant Equipment16.9 M28.6 M11.2 M
Slightly volatile
Capital Surpluse743.6 M708.2 M358 M
Slightly volatile
Preferred Stock Total Equity93.1 M105.9 M87.7 M
Slightly volatile
Short and Long Term Debt Total245 M486.3 M154.1 M
Slightly volatile
Other Liabilities192.4 M363 M131.7 M
Slightly volatile
Long Term Debt213 M361.7 M125.9 M
Slightly volatile
Long Term Debt Total172.1 M164 M84 M
Slightly volatile
Net Invested Capital433.7 M825.5 M306.4 M
Slightly volatile
Short and Long Term Debt113.1 M107.7 M58.6 M
Slightly volatile
Net Working Capital551.8 M691.2 M370.3 M
Slightly volatile
Short Term Debt105.8 M100.7 M26.4 M
Slightly volatile
Capital Stock10.6 K13.8 K7.9 K
Slightly volatile
Capital Lease Obligations20.2 M19 M16.4 M
Slightly volatile
Current Deferred Revenue86.1 M92.9 M107.2 M
Slightly volatile
Short Term Investments4.1 M4.4 M206.6 M
Slightly volatile
Non Current Liabilities Other7.5 M7.9 M277.8 M
Slightly volatile

Apellis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.5 M1.6 M12.9 M
Very volatile
Selling General Administrative577.8 M550.3 M162.4 M
Slightly volatile
Other Operating Expenses995.8 M948.4 M359.4 M
Slightly volatile
Research Development211.5 M295.9 M159.9 M
Slightly volatile
Total Operating Expenses888.4 M846.1 M333 M
Slightly volatile
Non Recurring21.2 M23.8 M26 M
Slightly volatile
Interest Income8.4 M13.1 M4.6 M
Slightly volatile
Reconciled Depreciation1.2 M1.6 M616.3 K
Slightly volatile
Tax Provision1.4 M1.7 M1.6 M
Slightly volatile
Selling And Marketing Expenses100.6 M95.8 M17.9 M
Slightly volatile

Apellis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation109.2 M104 M39.9 M
Slightly volatile
Begin Period Cash Flow280.2 M412.6 M211.4 M
Slightly volatile
Depreciation846.9 K1.6 M639.7 K
Slightly volatile
Other Non Cash Items113.5 M108.1 M29.1 M
Slightly volatile
Total Cash From Financing Activities8.4 M8.9 M166.6 M
Slightly volatile
End Period Cash Flow319.7 M467.8 M241.9 M
Slightly volatile
Change To Netincome183.7 M174.9 M77.7 M
Slightly volatile
Dividends Paid258.3 M290.6 M317.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.03.153820.6192
Very volatile
PTB Ratio15.528.552618.2591
Pretty Stable
Days Sales Outstanding17713388.4571
Slightly volatile
Book Value Per Share1.592.93711.7926
Slightly volatile
Average Payables3.4 M6.3 M4.6 M
Slightly volatile
Stock Based Compensation To Revenue0.160.170.2943
Pretty Stable
Capex To Depreciation0.250.262.2701
Slightly volatile
PB Ratio15.528.552618.2591
Pretty Stable
EV To Sales3.013.172319.3818
Very volatile
Inventory Turnover0.460.71720.3335
Slightly volatile
Days Of Inventory On Hand4845091.6 K
Pretty Stable
Payables Turnover3.081.87.3675
Slightly volatile
Sales General And Administrative To Revenue0.580.610.908
Slightly volatile
Average Inventory192 K216 K235.8 K
Slightly volatile
Research And Ddevelopement To Revenue0.280.29471.5592
Very volatile
Capex To Revenue3.0E-43.0E-40.0163
Slightly volatile
Cash Per Share3.353.71173.5806
Slightly volatile
Days Payables Outstanding193203580
Pretty Stable
Income Quality2.132.02460.9489
Slightly volatile
Current Ratio2.983.13618.2202
Slightly volatile
Tangible Book Value Per Share1.592.93711.7926
Slightly volatile
Receivables Turnover5.162.74097.8573
Slightly volatile
Graham Number2.743.083.3656
Slightly volatile
Shareholders Equity Per Share1.592.93711.7926
Slightly volatile
Debt To Equity1.11.31380.8695
Slightly volatile
Capex Per Share0.00240.00250.015
Pretty Stable
Revenue Per Share8.367.9653.7738
Slightly volatile
Interest Debt Per Share4.424.21061.9245
Slightly volatile
Debt To Assets0.230.45230.2252
Slightly volatile
Operating Cycle610642638
Slightly volatile
Price Book Value Ratio15.528.552618.2591
Pretty Stable
Days Of Payables Outstanding193203580
Pretty Stable
Ebt Per Ebit0.410.4351.0074
Pretty Stable
Company Equity Multiplier2.632.90492.8739
Slightly volatile
Long Term Debt To Capitalization0.360.50230.322
Slightly volatile
Total Debt To Capitalization0.380.56780.3361
Slightly volatile
Debt Equity Ratio1.11.31380.8695
Slightly volatile
Quick Ratio2.562.69567.9412
Slightly volatile
Net Income Per E B T1.090.92860.992
Slightly volatile
Cash Ratio1.371.44557.077
Slightly volatile
Days Of Inventory Outstanding4845091.6 K
Pretty Stable
Days Of Sales Outstanding17713388.4571
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.110.99311.0116
Slightly volatile
Price To Book Ratio15.528.552618.2591
Pretty Stable
Fixed Asset Turnover52.9650.433716.5449
Slightly volatile
Debt Ratio0.230.45230.2252
Slightly volatile
Price Sales Ratio3.03.153820.6192
Very volatile
Asset Turnover0.980.93350.3732
Slightly volatile
Gross Profit Margin0.980.89810.9016
Pretty Stable
Price Fair Value15.528.552618.2591
Pretty Stable

Apellis Fundamental Market Drivers

Forward Price Earnings46.2963
Cash And Short Term Investments467.8 M

Apellis Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue92.9 M86.1 M
Total Revenue1 B1.1 B
Cost Of Revenue102.2 M107.3 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 0.61  0.58 
Research And Ddevelopement To Revenue 0.29  0.28 
Revenue Per Share 7.97  8.36 
Ebit Per Revenue 0.06  0.06 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY